SEC Form 4 · accession 0001493152-26-041727

PROVECTUS BIOPHARMACEUTICALS, INC. · PVCT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CEO · Director · 10% Owner

Period of report

Sep 4, 2026

Accepted (ET)

Sep 8, 2026 · 10:13 am EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0000315545

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
8% Unsecured Convertible Promissory Note^F3,F4	$2.862	Sep 4, 2026	M	—	D	Sep 4, 2025	Sep 4, 2026	Series D-1 Convertible Preferred Stock	11,328	—	D
Series D-1 Convertible Preferred Stock^F1,F2	—	Sep 4, 2026	M	11,328	A	Sep 4, 2026	—	Common Stock	113,280	2,936,277	D

F1Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F2The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
F3The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
F4On September 04, 2026, the 2025 Note converted into 11,328 shares of Series D-1 Preferred Stock.